Genix Pharmaceuticals Corporation

As of April 30, 2026, Genix Pharmaceuticals Corporation carries a market capitalization of 1.22M, placing it among publicly traded companies globally. Its enterprise value stands at 2.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Genix Pharmaceuticals Corporation has 61.22M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, Genix Pharmaceuticals Corporation maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.

As of the close on September 16, 2026, Genix Pharmaceuticals Corporation's stock has declined approximately 33.33% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.05.

As of April 30, 2026, Genix Pharmaceuticals Corporation holds 11,255.00 in cash and equivalents against 1.15M in total debt, resulting in a net debt position of 1.14M. Total book value stands at -1.55M, with working capital of -1.55M providing operational flexibility.

Genix Pharmaceuticals Corporation produced -95,094.00 in operating cash flow over the twelve months ended April 30, 2026.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -7.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.